Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors

Abstract Wild type human AT 1 receptors (WT-AT 1 ) and mutant receptors, in which Asn 111 was replaced by glycine (N111G), alanine (N111A) and serine (N111S), or in which Asp 281 was replaced by alanine (D281A) or in which N111G and D281A replacements were combined, were transiently expressed in CHO-K1 cells. While the biphenyltetrazole compound candesartan dissociated slowly and behaved as an insurmountable antagonist for WT-AT 1 , it dissociated swiftly and only produced a rightward shift of the angiotensin Ang II- and -IV dose–response curves for inositol phosphate (IP) accumulation in cells expressing N111G. [ 3 H ]candesartan competition binding yielded the same potency order of the related biphenyltetrazoles for WT-AT 1 and mutated receptors, i.e. candesartan>EXP3174>irbesartan>losartan. Affinities were equal for WT-AT 1 and D281A and 40- to 400-fold lower for all Asn 111 mutants. Mutations did not affect the affinity of the peptide antagonist [Sar 1 Ile 8 ]Ang II (SARILE). Basal IP accumulation in cells with WT-AT 1 was not affected by any biphenyltetrazole antagonists and was increased by SARILE to 19% of the maximal Ang II stimulation. Basal IP accumulation was higher for cells expressing the Asn 111 -mutated receptors. For N111G, this accumulation was partially inhibited by all the biphenyltetrazoles upon long-term (18 hr) exposure. In these cells SARILE produced the same maximal stimulation as Ang II. Asn 111 -mutated AT 1 receptors are thought to mimic the pre-activated state of the wild type receptor and comparing the efficacy and affinity of ligands for such mutated receptors facilitate the distinction of partial (SARILE) and inverse (biphenyltetrazoles) agonists from true antagonists.